Liquid and Solid Rebiopsies in EGFR-Mutated NSCLC Patients

被引：0
|
作者：
Nunes, D. [1 ]
Dansin, E. [2 ]
Lamblin, C. [3 ]
Wasielewski, E. [1 ]
Descarpentries, C. [4 ]
Gregoire, V. [4 ]
Copin, M. C. [4 ]
Escande, F. [4 ]
Cortot, A. [1 ]
机构：
[1] Lille Univ Hosp, Thorac Oncol, Lille, France
[2] Ctr Oscar Lambret, Lille, France
[3] Clin La Louviere, Lille, France
[4] Ctr Biol & Pathol, Lille, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
T790M; Rebiopsies; EGFR;
D O I：
10.1016/j.jtho.2017.09.1531
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02-002
引用
收藏
页码：S2237 / S2238
页数：2
相关论文
共 50 条
  • [31] Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
    Qiao, Meng
    Jiang, Tao
    Liu, Xinyu
    Mao, Shiqi
    Zhou, Fei
    Li, Xuefei
    Zhao, Chao
    Chen, Xiaoxia
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (08) : 1267 - 1288
  • [32] Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab
    Rosell, Rafael
    Gonzalez-Cao, Maria
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (03) : 169 - 170
  • [33] Heterogeneous Resistance Mechanisms in Rebiopsies from EGFR-Mutated NSCLC: Transformation to SCLC; FGFR3 and T790M Mutations
    Urbanska, E.
    Grauslund, M.
    Melchior, L.
    Sorensen, J. B.
    Santoni-Rugiu, E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2203 - S2203
  • [34] Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients
    Hackner, Klaus
    Buder, Anna
    Hochmair, Maximilian J.
    Strieder, Matthaeus
    Grech, Christina
    Fabikan, Hannah
    Burghuber, Otto C.
    Errhalt, Peter
    Filipits, Martin
    [J]. CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2021, 15
  • [35] Disease Monitoring of EGFR-mutated NSCLC Patients Treated with TKIs via EGFR Status in Circulating ctDNA
    Li, Y.
    Xu, Z.
    Wang, S.
    Zhu, Y.
    Ma, D.
    Mu, Y.
    Ying, J.
    Xing, P.
    Li, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S445 - S445
  • [36] Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
    Baldacci, Simon
    Mazieres, Julien
    Tomasini, Pascale
    Girard, Nicolas
    Guisier, Florian
    Audigier-Valette, Clarisse
    Monnet, Isabelle
    Wislez, Marie
    Perol, Maurice
    Do, Pascal
    Dansin, Eric
    Leduc, Charlotte
    Leprieur, Etienne Giroux
    Moro-Sibilot, Denis
    Tulasne, David
    Kherrouche, Zoulika
    Labreuche, Julien
    Cortot, Alexis B.
    [J]. ONCOTARGET, 2017, 8 (62) : 105103 - 105114
  • [37] Liquid Biopsy and PET Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC
    Leonetti, A.
    Bola, S.
    Minari, R.
    Scarlattei, M.
    Buti, S.
    Bordi, P.
    Baldari, G.
    Gnetti, L.
    Sammartano, A.
    Migliari, S.
    Cosenza, A.
    Ferri, L.
    Bonatti, F.
    Mastrodomenico, L.
    Ruffini, L.
    Tiseo, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S610 - S610
  • [38] Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinib
    Wu, Chen-Te
    Hsu, Ping-Chih
    Chang, John Wen-Cheng
    Chang, Ching-Fu
    Huang, Chen-Yang
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Fang, Yueh-Fu
    Wu, Chiao-En
    [J]. THORACIC CANCER, 2023, 14 (25) : 2548 - 2557
  • [39] A retrospective analysis of locally advanced EGFR-mutated NSCLC patients with durvalumab after chemoradiotherapy
    Uchida, Yoshiyasu
    Ninomiya, Takashi
    Harada, Daijiro
    Kozuki, Toshiyuki
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S488 - S488
  • [40] Depth of Response to First-Line EGFR TKI Does Not Predict Survival in EGFR-Mutated NSCLC Patients
    Wu, Ting-Hui
    Hsiue, Emily
    Lee, Jih-Hsiang
    Yang, James Chih-Hsin
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S386 - S387
12345